The DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Open accessAbstract
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials.Recent developments Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is crucial to find ways to reduce the need for PET scans due to their relative inaccessibility and costliness, while still preserving the ability to estimate the load and distribution of AD pathology as accurately and comprehensively. 12 , 13”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a major component of NFTs, tau protein exhibits a spatial and temporal distribution that strongly correlates with clinical symptoms, making it a highly specific pathological biomarker in AD patients.152”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Tau‐PET is often considered a state‐of‐the‐art outcome in AD research studies, a very accurate prognostic tool in patients with AD, and frequently used in clinical trials for AD during screening and to monitor treatment effects. 12 , 14 , 15 , 16”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [12]
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citation
Cited by
Sorted by citations
Items 201–300 of 557
Twenty years of therapeutic development in tauopathy mouse models: a scoping review
Langness, V. F., Simmons, D. A., McHugh, T. L. M., Butler, R. R., Zhou, J., Liu, H., Yang, T., Ellerby, L., & Longo, F. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70578 · Cited by 9
Wang, Y., Zhan, D., & Wang, L. (2023) · PubMed Central · Cited by 9
Obstructive sleep apnea and dementia: A role to play?
Kinugawa, K. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.08.006 · Cited by 9
Current Diagnostic and Treatment Methods of Alzheimer’s Disease: A Narrative Review
Dafre, R., & Wasnik, P. (2023) · Cureus · doi:10.7759/cureus.45649 · Cited by 11
Friends and Foes in Alzheimer’s Disease
Pauwels, E. K. J., & Boer, G. J. (2023) · Medical Principles and Practice · doi:10.1159/000534400 · Cited by 10
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 10
Arastoo, M., Penny, L. K., Lofthouse, R. A., Abdallah, A., Abrahamsson, A., Marini, P., Melis, V., Riedel, G., Harrington, C. R., Wischik, C. M., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01561-1 · Cited by 9
Calabria, F. F., Leporace, M., Cimini, A., Ricci, M., Travascio, L., & Bagnato, A. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206172 · Cited by 8
Survey among experts on the future role of tau‐PET in clinical practice and trials
Vermeiren, M. R., Calandri, I. L., van der Flier, W. M., van de Giessen, E., & Ossenkoppele, R. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70033 · Cited by 10
Self-citationReview on pathogenesis and treatment of Alzheimer's disease
Cai, J., Liu, Y., & Fan, H. (2024) · Developmental Dynamics · doi:10.1002/dvdy.762 · Cited by 10
Potential biofluid markers for cognitive impairment in Parkinson’s disease
Chen, J., Liang, C., Wang, F., Zhu, Y., Zhu, L., Chen, J., Liu, B., & Yang, X. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00592 · Cited by 8
Advances in neural stem cells in aging and age-related neurodegenerative diseases
Zhong, R., Huang, W., Chen, C., Zhang, B., Pu, J., & Zhang, F. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.32 · Cited by 9
Bridging the Gap: The Neuro-immune Axis as a Key Player in Neurodegenerative Disorders
Liu, T., Wu, H., & Wei, J. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01439-8 · Cited by 9
Guo, C., Ruan, H., Li, W., Liu, Y., Mahaman, Y. A. R., Guo, Q., Zhou, Y., Liu, R., Wang, J., Zhou, C., et al. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01445-w · Cited by 8
Biological applications of graphene-based nanomaterials in neurodegenerative diseases
Zhu, R.-K., Shi, J. Y., Zhou, H.-J., Ge, L., Yin, W.-H., Zeng, H., & Wang, X. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102064 · Cited by 9
Yu, Q., Li, L., Yu, S., Han, J., Cheng, Q., Cui, Z., Chen, H., Li, M., & Lu, Z. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04490-z · Cited by 9
Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy
Barnwal, N., Dubey, S., & Tiwari, P. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002408089250912080734 · Cited by 14
Roh, H. W., Chang, Y. Y., Kim, K. Y., Jeon, S. Y., Wang, S., Kim, E., Bae, J. N., & Ryu, S. (2026) · Psychiatry Investigation · doi:10.30773/pi.2025.0400 · Cited by 8
Bogdan, S., Puścion‐Jakubik, A., Klimiuk, K., Socha, K., Kochanowicz, J., & Gorodkiewicz, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216855 · Cited by 9
Hsu, C., Wang, S., Lin, H., Lin, E. S., Yang, F., Chang, C., & Wei, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073919 · Cited by 9
Wan, K., Yin, W., Tang, Y., Zhu, W., Wang, Z., Zhou, X., Zhang, W., Zhang, C., Yu, X., Zhao, W., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221100 · Cited by 9
Identification of Molecular Correlations of GSDMD with Pyroptosis in Alzheimer's Disease
Song, T., Chen, Y., Li, C., Yao, Y., Ma, S., Yazhen, S., & Cheng, J. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073285497240226061936 · Cited by 9
Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
Ishiguro, T., & Kasuga, K. (2024) · Brain Sciences · doi:10.3390/brainsci14090859 · Cited by 7
SENP1 inhibits aerobic glycolysis in Aβ1-42-incubated astrocytes by promoting PUM2 deSUMOylation
Liu, Q., Jiang, M., Wang, Z., Meng, J., Jia, H., Li, J., Lin, J., Guo, L., & Gao, L. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-09986-6 · Cited by 7
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Osse, A. M. L., Kinney, J. W., & Cummings, J. L. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70050 · Cited by 7
Ma, L., Wang, J., Zhou, R., Chen, M., Huang, Z., & Lin, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528919 · Cited by 9
Aguila, A. L., Lorenzini, L., Janahi, M., Barkhof, F., & Altmann, A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01753-3 · Cited by 11
Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes
Boccalini, C., Mathoux, G., Hristovska, I., Ribaldi, F., Peretti, D. E., Arnone, A., Scheffler, M., Frisoni, G. B., Hansson, O., Vogel, J. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213950 · Cited by 7
Self-citationLei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7
Yuan, Z., Wang, F., Wei, H., Li, X., Wei, W., Luo, S., Zhang, Y., Wei, X., Wang, G., Liang, H., et al. (2025) · Virulence · doi:10.1080/21505594.2025.2580102 · Cited by 7
Devanarayan, V., Horie, K., Wildsmith, K. R., Doherty, T., Andreozzi, E. M., Charil, A., Sachdev, P., Kramer, L. D., Dhadda, S., & Irizarry, M. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70881 · Cited by 7
Liu, Z., Li, X., Wang, Q., Liu, K., Zeng, W., Li, D., Zhao, K., Ma, Y., Long, H., Zhang, S., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22156 · Cited by 7
Biomarker Identification for Alzheimer’s Disease Using a Multi-Filter Gene Selection Approach
Pashaei, E., Pashaei, E., & Aydın, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051816 · Cited by 8
Diagnostic Potential of Eye Movements in Alzheimer’s Disease via a Multiclass Machine Learning Model
Song, J., Huang, H., Liu, J., Wu, J., Chen, Y., Wang, L., Zhong, F., Wang, X., Lin, Z., Yan, M., et al. (2024) · Cognitive Computation · doi:10.1007/s12559-024-10346-5 · Cited by 7
MRI-free processing of tau PET images for early detection
Carlson, M. L., Smith, V., Johns, E., Young, C. B., Vossler, H. A., Ward, T. J., Harrison, T. M., Tosun, D., Hohman, T. J., Landau, S. M., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00369 · Cited by 6
Liu, X., Wang, W., Nie, Q., Liu, X., Sun, L., Ma, Q., Zhang, J., & Wei, Y. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-024-01343-7 · Cited by 6
Wang, Z., Zhang, K., Huang, M., Shang, D., He, X., Wu, Z., Xu, Y., & Zhang, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.019 · Cited by 6
The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer’s Disease
Katsipis, G., Tzekaki, E. E., Iasonidou, S., & Pantazaki, Α. A. (2025) · Cells · doi:10.3390/cells14181424 · Cited by 6
Hu, M., Moloney, C. M., Przybelski, S. A., Algeciras‐Schimnich, A., Therneau, T. M., Fought, A. J., Rothberg, D. M., Nguyen, A. T., Reichard, R. R., Dickson, D. W., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01852-1 · Cited by 8
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 8
Hromádková, L., Kim, C., Haldiman, T., Peng, L., Zhu, X., Cohen, M. L., de Silva, R., & Safar, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01133-0 · Cited by 6
Fan, X., Initiative, A. D. N., Li, H., Liu, L., Zhang, K., Zhang, Z., Chen, Y., Wang, Z., He, X., Xu, J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230705 · Cited by 9
Ma, W., Tang, B., Zhang, H., Qu, Y., Luan, J., Wang, K., Chen, W., Wang, X., Liu, X., Zhao, H., et al. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344485 · Cited by 6
Escape from X-chromosome inactivation and sex differences in Alzheimer’s disease
Song, Q.-H., Zhao, K.-X., Huang, S., Chen, T., & He, L. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0108 · Cited by 7
Rottlerin Enhances the Autophagic Degradation of Phosphorylated Tau in Neuronal Cells
Kam, M. K., Park, J.-Y., Yun, G. H., Sohn, H., Park, J., Choi, J., Koh, Y. H., & Jo, C. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04182-9 · Cited by 6
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Zetterberg, H., Mattsson, N., Janelidze, S., Blennow, K., & Hansson, O. (2022) · medRxiv · doi:10.1101/2022.08.22.22279052 · Cited by 6
Self-citationLi, W., Wang, Z., Zhu, Q., & Tian, P. (2025) · Molecules · doi:10.3390/molecules30132704 · Cited by 5
Challenges and opportunities in nanotherapeutics targeted for central nervous system disorders
Yong, J. M., Hakobyan, K., Mahmud, S. A. Z., Johnson, D., Lee, J., Diwan, A. D., Gu, Z., Moalem‐Taylor, G., & Mao, G. (2025) · Nanoscale · doi:10.1039/d5nr02463c · Cited by 5
Liu, S., Yan, J., & Dong, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1661706 · Cited by 6
Tang, J., Zhang, Y., Wang, Y., Fu, Y., Qi, J., Xiang, A., Zhao, R., Tan, G., Deng, H., Zhou, X., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s557031 · Cited by 5
Xiao, J., Yi, L. I. U., Peng, M., Ma, J., Lei, S., Chen, Y., Liu, S., Zhao, X., Lu, D., & Sun, Q. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01961-5 · Cited by 5
Systems genetics identifies methionine as a high risk factor for Alzheimer's disease
Wang, C., Hei, Y., Liu, Y., Bajpai, A. K., Li, Y., Guan, Y., Xu, F., & Yao, C. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1381889 · Cited by 5
Dietary Supplements and Phytopharmaceuticals for the Management of Cognitive Disorders
Nagori, K., Pradhan, M., Nakhate, K. T., Thakur, A., Patle, K., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-63677-6_9 · Cited by 6
The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study
Vermeiren, M. R., Somsen, J. F., Luurtsema, G., Reesink, F. E., Verwey, N. A., Hempenius, L., Tolboom, N., Biessels, G. J., Biesbroek, J. M., Vernooij, M. W., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01588-4 · Cited by 5
Self-citationFavero, F., Re, A., Dason, M. S., Gravina, T., Gagliardi, M., Mellai, M., Corazzari, M., & Corà, D. (2024) · Biology Direct · doi:10.1186/s13062-024-00541-7 · Cited by 5
Chen, Y., Li, C., Yao, Y., & Yazhen, S. (2024) · Current Alzheimer Research · doi:10.2174/0115672050338777241028071955 · Cited by 6
Wei, M., Zhang, Y., Wang, M., Zhong, J., Chai, W., Hu, W., Tao, F., Wang, L., Zhang, Q., Yu, X., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70114 · Cited by 5
Ye, X., Wang, X., Wang, Y., & Lin, H. Y. (2025) · Preventive Medicine · doi:10.1016/j.ypmed.2025.108307 · Cited by 5
Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects
Martínez‐Dubarbie, F., López‐García, S., Lage, C., Molfetta, G. D., Fernández‐Matarrubia, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., Jiménez-Bonilla, J. F., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231479 · Cited by 4
Aqueous and Plasma Levels of Phosphorylated Tau 181 in Individuals with Normal Cognition
Patel, H. H., Wisely, C. E., Robbins, C. B., Parker, D., Challa, P., Grewal, D. S., & Fekrat, S. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240279 · Cited by 5
Valles‐Salgado, M., Gil‐Moreno, M. J., Curiel, R. E., Delgado‐Álvarez, A., Ortega‐Madueño, I., Delgado‐Alonso, C., Palacios‐Sarmiento, M., López‐Carbonero, J. I., Cárdenas, M. C., Matías‐Guiu, J., et al. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1373541 · Cited by 5
Current status of prevention strategies adapted for Alzheimer's disease
Singh, A., Sethi, P., Ghosh, S., Singh, D. K. K., Rohatgi, S., Singh, P. K., & Sinha, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00004-5 · Cited by 5
The Current Role of Tau PET Imaging in Neurodegeneration
Vanderlinden, G., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.002 · Cited by 7
Pregnancy hypertension is associated with higher p-tau217 in healthy midlife women
Yong, E., Wong, B. W. X., Tan, D. Y. Z., Shen, L., Thia, B. W. Q., Chong, J. R., & Chen, C. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100316 · Cited by 4
Xing, Z., Jiang, X., Yang, W., Wang, Y., Zhang, X., & Zhao, C. (2025) · Current Alzheimer Research · doi:10.2174/0115672050399032250715043316 · Cited by 4
The association of the Wnt/β-catenin signaling pathway with Alzheimer's disease
Ma, J., Liu, Y., Lu, D., & Sun, Q. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110754 · Cited by 5
Shi, Q., Hou, J., Peng, X., Xu, Z., Wang, Y., & Cao, D. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102943 · Cited by 5
Yu, H., Zhang, X., Liu, Z., & Zhang, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01488 · Cited by 4
Lab-on-a-chip for biomarker detection: advances, practical applications, and future perspectives
Xu, T., Bai, H., Hu, J., Zhang, L., Zhuang, W., Zou, C., Yao, Y., Hu, W. W., & Huang, J. (2026) · Lab on a Chip · doi:10.1039/d5lc00986c · Cited by 7
Keshavan, A., Wiltshire, K., Wee, R. W. S., Belio, I. G., Tucker, K., Hart, M., Lunn, M. P., David, M. C. B., Rizzo, L., Sadeghi‐Alavijeh, O., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71147 · Cited by 4
Wang, Y., Lv, R., Jiang, Z. H. E. N. G. M., Liu, Y., Zhang, J., Zhao, Z., Liu, Y., Zheng, Y., Liu, B., Clauw, D., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03542-2 · Cited by 8
Khattab, N. A., El-Kadem, A. H., Goda, A. E., El‐Mahdy, N. A., & El‐Shitany, N. A. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115814 · Cited by 4
Therriault, J., Gauthier, S. G., & Rosa‐Neto, P. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.52 · Cited by 4
Proteomic study of left ventricle and cortex in rats after myocardial infarction
Chang, M., Wang, H., Lei, Y., Yang, H., Xu, J., & Tang, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-56816-6 · Cited by 4
Tau Protein Accumulation Trajectory-Based Brain Age Prediction in the Alzheimer’s Disease Continuum
Wang, M., Wei, M., Wang, L., Song, J., Rominger, A., Shi, K., & Jiang, J. (2024) · Brain Sciences · doi:10.3390/brainsci14060575 · Cited by 4
Management of MCI in the Outpatient Setting
Abramowitz, A., & Weber, M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01514-3 · Cited by 3
Biomarkers and Alzheimer’s disease: a bibliometric analysis
Yang, L., Zeng, J., Li, L., & Zhang, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1456824 · Cited by 4
Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment
Trivedi, P., Forrest, K., Fisher, D. W., Winstone, J. K., McMillan, P. J., Valentine, M., Postupna, N. O., Wilson, A. M., Bajwa, T. S., MacCoss, M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70481 · Cited by 6
Neuropathologic Changes in People With Essential Tremor With Dementia
Wainman, E., Berry, D. S., Hernandez, N. C., Guy, T. O., Cosentino, S., Faust, P. L., & Louis, E. D. (2025) · Neurology · doi:10.1212/wnl.0000000000214310 · Cited by 5
Hou, Y., Chueh, T.-I., Lu, K., Liu, Y., Chen, T.-H., Liu, S., & Chen, R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230747 · Cited by 4
Interplay between glypican-1, amyloid-β and tau phosphorylation in human neural stem cells
Cheng, F., Fransson, L., & Mani, K. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.005 · Cited by 5
Zyuz’kov, G. N., Miroshnichenko, L. A., Polyakova, T. Y., Simanina, E. V., & Chaikovskii, A. V. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249302264240715060630 · Cited by 4
Borland, E., Mattsson, N., Tideman, P., Initiative, T. A. D. N., Stomrud, E., Hansson, O., & Palmqvist, S. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14305 · Cited by 6
Self-citationAmyloid-β and tau PET scans predict clinical progression in cognitively unimpaired people
(2022) · Nature Medicine · doi:10.1038/s41591-022-02071-z · Cited by 4
A fluid biomarker accurately detects tau aggregate pathology in Alzheimer’s disease
(2023) · Nature Medicine · doi:10.1038/s41591-023-02468-4 · Cited by 4
Han, S.-L., Ou, Y., Han, B.-L., Guo, H., Chi, H., Huang, Y., Wang, H.-F., & Tan, L. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231093 · Cited by 4
Wei, H., Wu, C., Yuan, Y., & Lai, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1249682 · Cited by 3
Li, W., Zhao, P., Li, Y., Wu, S., & Tian, P. (2025) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.4c05975 · Cited by 3
Li, W., Fan, D., Sun, Q., Wang, L., Huang, B., Yu, Z., Tian, D., Shen, Y., Tan, C., Zeng, G., et al. (2025) · Aging Cell · doi:10.1111/acel.70036 · Cited by 3
Novel strategies for targeting tau oligomers in neurodegenerative diseases
Lin, J., Li, H., Jiang, L., & Li, J. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13117-w · Cited by 3
Wang, X., Cui, L., Kong, L., Zou, S.-F., & Zhao, X. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107219 · Cited by 3
Membrane sensitization biosensor based on magnetic inducing for Tau protein detection
Wang, H., Wang, B., Bai, J., Yao, P., Guo, X., Ge, Y., Sang, S., Dong, X., & Zhao, D. Q. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07386-5 · Cited by 3
Kumar, A., Binette, A. P., Bali, D., Janelidze, S., Stomrud, E., Palmqvist, S., Vogel, J. W., Hansson, O., & Mattsson, N. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf353 · Cited by 3
Self-citationPhytochemicals as modulators of Astrocytes in Alzheimer's disease: A therapeutic perspective
Wang, S., Zhang, Z., Liu, Y., Gao, S., Wang, L., Yang, J., & Wang, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157347 · Cited by 3
Wang, J., Yao, K.-Y., Li, J., Wong, D. W., & Cheung, J. C. (2025) · Biosensors · doi:10.3390/bios15120784 · Cited by 4
Dulewicz, M., Kac, P. R., Ortiz, F. G., Karikari, T. K., Kulczyńska‐Przybik, A., Mroczko, B., Turton, M., Harrison, P., Maler, M., Oberstein, T. J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70313 · Cited by 4
Huang, S., Wu, J., & He, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1683204 · Cited by 4
Applications of Endovascular Brain–Computer Interface in Patients with Alzheimer’s Disease
Sun, Y., Chen, D., Ye, Q., You, Z., Zhao, Z., Shi, J., Sun, H., Li, S., Xu, Y., Xu, Y., et al. (2025) · Research · doi:10.34133/research.1049 · Cited by 3
Fu, J. Q., Ding, C., Li, W., Lei, J., Wang, H., Meng, L., Lin, X., Chen, W., & Gao, H. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115613 · Cited by 4
Nazli, D., Ipekgil, D., Poyraz, Y. K., Can, K., Okmen, I., Turhanlar‐Sahin, E., Serdar, B. S., Koçtürk, S., & Ozhan, G. (2026) · Journal of Neuroscience Research · doi:10.1002/jnr.70119 · Cited by 3
Metadata
- Authors
- Ossenkoppele, R., van der Kant, R., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Ossenkoppele, Rik
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 21
- Issue
- 8
- Pages
- 726-734
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4281564421
- Cited by
- 557
- References
- 79
- Citations by year
- 2026: 127 · 2025: 174 · 2024: 142 · 2023: 98 · 2022: 15
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau pathology, tau biomarkers, tau PET tracers, phosphorylated tau, cerebrospinal fluid biomarkers, blood-based biomarkers, anti-tau therapy, clinical trial participant selection, early disease detection, tau immunotherapy, tau aggregation inhibitors, dementia diagnosis, mild cognitive impairment, primary care
- MeSH terms
- Alzheimer Disease, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neuroimaging, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
